23ME-01473, an Fc Effector–Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell–Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation
This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.
Authors
- Kimberline Y. Gerrick
- Shruti Yadav (ORCID: https://orcid.org/0000-0002-0958-9304)
- Danielle Kellar
- Pranidhi Sood (ORCID: https://orcid.org/0000-0002-6219-4512)
- Patrick Koenig (ORCID: https://orcid.org/0000-0003-1898-6392)
- Mauro Poggio (ORCID: https://orcid.org/0000-0003-4941-0927)
- Germaine Fuh
- Dina Ayupova
- Zahra Bahrami Dizicheh
- Alex Owyang
- Clifford Hom
- Maike Schmidt (ORCID: https://orcid.org/0000-0001-9062-1828)
- Susanne Tilk (ORCID: https://orcid.org/0000-0002-9156-9360)
- Debasish Sen (ORCID: https://orcid.org/0000-0001-9879-8345)
- Pierre Fontanillas (ORCID: https://orcid.org/0000-0002-8944-4454)
- Nives Ivić (ORCID: https://orcid.org/0000-0002-5952-6133)
- Caroline Bonnans
- Shashank Bharill
- I-Ling Chen
- Anh N. Diep (ORCID: https://orcid.org/0000-0001-6202-6394)
- Joel S. Benjamin
- Shi Shi
- Abigail Jarret
Institutions
- Rapt Therapeutics (United States) (US)
- ProterixBio (United States) (US)
- 23andMe (United States) (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0478
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.80